MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

US GAAP

Reporting scope

Consolidated group

Auditor

Ernst & Young Ltd.

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Management of the Group has evaluated relevant conditions, events disclosed in Note 13 subsequent events, available resources and management plans that were known or reasonably known as at the date of issue of these financial statements and concluded that no substantial doubts exist concerning the ability of the Group entities to continue as going concerns for at least the next 12 months.”

Significant events

• “In 2024, Clinical Designs Limited (CDL) and Mundipharma Corporation Limited (MCL) were voluntarily liquidated.”
• “In 2024, the license agreement with Genewal Co. Limited was terminated.”
• “In 2024, the license agreement with Endoceutics Inc. was terminated.”
• “In 2024, the Thornton & Ross Limited agreement was novated to iNova Pharmaceuticals (Singapore) Pte Limited.”
• “On January 31, 2024, the Group sold the remaining Consumer Health business to iNova. The Group received consideration of $66,760,000 and recorded a gain on disposal of intangible assets of $64,597,000.”
• “On June 28, 2024, MILB entered a License and Commercialization Agreement, transferring its rights in morphine sulfate pentahydrate (Sevredol®) in New Zealand to Douglas Pharmaceuticals Limited for $456,000 (NZD750,000). The transaction resulted in a gain on disposal of intangible assets of $334,000, of which $167,000 was passed on to NAPP per the Collaboration agreement in note 2.”
• “In 2024, the Company settled claims totalling EUR2.6M ($2.8m). and a payable to the associated company has been recorded in the Company to indemnify the associated companies for an amount equal to the unsettled claims for damages of EUR0.9m ($0.9m). Following a settlement agreed on all cases in 2025, the Company estimates the possible remaining claims for damages at EURnil ($nil) million and as such a release of the provision of EUR2.4m ($2.9m) was recorded in 2024.”
• “The reserve (appropriation of retained earnings) was released in 2024 as discounted securities were settled from the restricted funds.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

1

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -7.5%

  £33,945,145 → £31,415,864

• Cash

  +15.3%

  £16,647,887 → £19,186,805

• Net assets

  -1.9%

  £50,897,702 → £49,949,592

• Employees

  —

  Not reported

• Operating profit

  +56.7%

  £3,730,912 → £5,845,070

• Profit before tax

  +1,524%

  £3,033,358 → £49,260,934

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers